250 Participants Needed

Adoptive Cell Therapy for Cancer

Recruiting at 48 trial locations
UG
EG
AP
Overseen ByAdaptimmune Patient Enquiries Call Center
Age: Any Age
Sex: Any
Trial Phase: Phase 1
Sponsor: Adaptimmune
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial investigator for guidance based on your medical history.

What makes GSK adoptive cell therapy unique compared to other cancer treatments?

GSK adoptive cell therapy is unique because it uses genetically engineered T-cells that specifically target the NY-ESO-1 antigen, which is found in certain cancers like synovial sarcoma and melanoma. This approach allows for precise targeting of cancer cells, potentially leading to better outcomes with fewer side effects compared to traditional treatments.12345

Research Team

A

Adaptimmune

Principal Investigator

Adaptimmune

Eligibility Criteria

This trial is for people who have previously received GSK adoptive cell therapy as a treatment for tumors. They should be able to consent, have finished or withdrawn from a related GSK study, or completed treatment through managed access. Participants must follow local contraception guidelines and have taken at least one dose of the therapy.

Inclusion Criteria

The investigator is responsible for review of medical history
I am able to understand and sign the consent form.
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
See 3 more

Exclusion Criteria

N/A

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive ADP adoptive cell therapy

Not specified

Long-term Follow-up

Participants are monitored for safety following last adoptive cell therapy infusion

15 years

Treatment Details

Interventions

  • GSK adoptive cell therapy
Trial OverviewThe trial is monitoring the long-term safety of GSK's adoptive cell therapy in patients up to 15 years after their last infusion. It aims to track any late-emerging side effects and overall health outcomes following the treatment.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Participants receiving ADP adoptive cell therapyExperimental Treatment1 Intervention

GSK adoptive cell therapy is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as GSK3377794 for:
  • Synovial sarcoma
🇺🇸
Approved in United States as GSK3377794 for:
  • Synovial sarcoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

Adaptimmune

Lead Sponsor

Trials
25
Recruited
10,000+

GlaxoSmithKline

Lead Sponsor

Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley profile image

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron profile image

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School

Findings from Research

Adoptive cell therapy using chimeric antigen receptor T cells has been revolutionary for treating blood cancers, but it has not been as effective for solid tumors, highlighting a need for improved strategies.
Recent advancements, such as modified T cell receptors targeting specific tumor-associated antigens and the use of tumor-infiltrating lymphocytes, have shown promise in treating certain solid tumors like synovial sarcoma and metastatic cervical cancer.
Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond.Moreno, V., Hernandez, T., de Miguel, M., et al.[2021]
Adoptive T-cell therapy involves using tumor-fighting T-cells that are either taken from the patient or donors, modified in the lab, and then reintroduced into the patient to target and eliminate cancer cells.
Over the past 30 years, various strategies have evolved in adoptive T-cell therapy, leading to more precise targeting of tumors and improved effectiveness in treating cancer.
[Advances in application of adoptive T-cell therapy for cancer patients].Jixia, Z., Chengyan, Z., Pingli, W.[2023]
Adoptive T-cell therapy is a promising cancer treatment that enhances the body's immune response by using tumor-reactive T cells, which can provide high specificity and long-term protection against tumors.
Recent advancements in understanding T-cell behavior and new technologies have improved the ability to isolate and enhance T cells, making this therapy more effective when combined with other treatments.
The use of endogenous T cells for adoptive transfer.Yee, C.[2023]

References

Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond. [2021]
[Advances in application of adoptive T-cell therapy for cancer patients]. [2023]
The use of endogenous T cells for adoptive transfer. [2023]
Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. [2020]
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. [2023]